PCSK9: the Critical Role of Familial Hypercholesterolemia from Discovery to Benefit for all
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cardiology and Cardiovascular Medicine,Pharmacology,General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s10557-016-6690-1.pdf
Reference31 articles.
1. Muller C. Xanthomata, Hypercholesterolemia. Angina Pectoris Acta Medica Scandinavica. 1938;95(S89):75–84.
2. Goldstein JL, Brown MS. Binding and degradation of low density lipoproteins by cultured human fibroblasts: comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J Biol Chem. 1974;249:5153–62.
3. Goldstein JL, Brown MS: Familial hypercholesterolemia. Identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc Natl Acad Sci U S A 1973;70:2804–2808.
4. Brown MS, Ho YK, Goldstein JL. The low-density lipoprotein pathway in human fibroblasts: relation between cell surface receptor binding and endocytosis of low-density lipoprotein. Ann N Y Acad Sci. 1976;275:244–57.
5. Mabuchi H, Haba T, Tatami R, et al. Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. N Engl J Med. 1981;305:478–82.
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Special Patient Populations;Clinical Lipidology;2024
2. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia;Journal of the American College of Cardiology;2020-02
3. Molecular aspects of hypercholesterolemia treatment: current perspectives and hopes;Annals of Medicine;2018-04-10
4. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia;European Heart Journal;2017-10-16
5. Cardiovascular Safety of Evolocumab: a Systematic Review and Meta-Analysis;Cardiovascular Drugs and Therapy;2016-11-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3